Skip to main content

Table 1 Composition of the prostate prognosis tissue microarray. Percentage in the column “Study cohort on TMA” refers to the fraction of samples across each category. Percentage in column “Biochemical relapse among categories” refers to the fraction of samples with biochemical relapse within each parameter in the different categories

From: Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion

 No. of patients (%)
Study cohort on TMA
(n = 17,747)
Biochemical relapse among categories
Follow-up (mo)
 n14,464 (81.5%)3612 (25%)
 Mean56.3
 Median48
Age (y)
  ≤ 50433 (2.4%)66 (15.2%)
 51–594341 (24.5%)839 (19.3%)
 60–699977 (56.4%)2073 (20.8%)
  ≥ 702936 (16.6%)634 (21.6%)
Pretreatment PSA (ng/ml)
  < 42225 (12.6%)313 (14.1%)
 4–1010,520 (59.6%)1696 (16.1%)
 10–203662 (20.8%)1043 (28.5%)
  > 201231 (7%)545 (44.3%)
pT stage (AJCC 2002)
 pT211,518 (65.2%)1212 (10.5%)
 pT3a3842 (21.7%)1121 (29.2%)
 pT3b2233 (12.6%)1213 (54.3%)
 pT485 (0.5%)63 (74.1%)
Gleason grade
  ≤ 3 + 33570 (20.3%)264 (7.4%)
 3 + 49336 (53%)1436 (15.4%)
 3 + 4 Tert.5798 (4.5%)165 (20.7%)
 4 + 31733 (9.8%)683 (39.4%)
 4 + 3 Tert.51187 (6.7%)487 (41%)
  ≥ 4 + 4999 (5.7%)531 (53.2%)
pN stage
 pN010,636 (89.4%)2243 (21.1%)
 pN+1255 (10.6%)700 (55.8%)
Surgical margin
 Negative14,297 (80.8%)2307 (16.1%)
 Positive3388 (19.2%)1304 (38.5%)
  1. Numbers do not always add up to 17,747 in the different categories because of cases with missing data. Abbreviation: AJCC American Joint Committee on Cancer